Bright Biotech, is a British contract development and manufacturing organization (CDMO) specializing in the production of recombinant proteins for R&D, therapeutic, cosmetical, agri-food, and industrial applications. The company is working on harnessing protein from chloroplasts of plants to develop cultured meat growth factors as opposed to animal cells, which are widely used in the industry. According to the company, chloroplast-based expression is light-driven, robust, and ultra-scalable and will help to address supply bottlenecks that are hindering the commercial application of growth factors in the industry.
Funding and financials
In November 2022, the company raised USD 3.2 million in an oversubscribed seed funding round led by Food Lab with participation from Big Idea Ventures, CPT Capital, and others. The funding was to be used on the next phase of R&D and additional hires to the team.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.